Related Experiment Video
Updated: Jul 13, 2026
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies
Peter Hau1, Piotr Jachimczak, Reimar Schlingensiepen
1Department of Neurology, University of Regensburg, Germany.
Abstract:
Transforming growth factor-beta2 (TGF-beta2) is known to suppress the immune response to cancer cells and plays a pivotal role in tumor progression by regulating key mechanisms including proliferation, metastasis, and angiogenesis. For targeted protein suppression the TGF-beta2-specific antisense oligodeoxynucleotide AP 12009 was developed. In vitro experiments have been performed to prove specificity and efficacy of the TGF-beta2 inhibitor AP 12009 employing patient-derived malignant glioma cells as well as peripheral blood mononuclear cells (PBMCs) from patients. Clinically, the antisense compound AP 12009 was assessed in three Phase I/II-studies for the treatment of patients with recurrent or refractory malignant (high-grade) glioma WHO grade III or IV. Although the study was not primarily designed as an efficacy evaluation, prolonged survival compared to literature data and response data were observed, which are very rarely seen in this tumor indication. Two patients experienced long-lasting complete tumor remissions. These results implicate targeted TGF-beta2-suppression using AP 12009 as a promising novel approach for malignant gliomas and other highly aggressive, TGF-beta-2-overexpressing tumors.
Insights
Targeted suppression of transforming growth factor-beta2 (TGF-beta2) using AP 12009 showed promise in treating malignant gliomas. This approach led to prolonged survival and complete tumor remissions in patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Transforming growth factor-beta2 (TGF-beta2) is implicated in cancer progression by suppressing immune responses and promoting tumor growth.
- TGF-beta2 regulates critical cancer mechanisms such as proliferation, metastasis, and angiogenesis.
- Malignant gliomas are aggressive tumors often associated with TGF-beta2 overexpression.
Purpose of the Study:
- To evaluate the specificity and efficacy of the TGF-beta2-specific antisense oligodeoxynucleotide AP 12009.
- To assess the therapeutic potential of AP 12009 in patients with recurrent or refractory high-grade gliomas (WHO grade III or IV).
Main Methods:
- In vitro studies using patient-derived malignant glioma cells and peripheral blood mononuclear cells (PBMCs) to assess AP 12009.
- Clinical assessment of AP 12009 in three Phase I/II clinical trials for malignant glioma patients.
Main Results:
- In vitro experiments confirmed the specificity and efficacy of AP 12009.
- Clinical trials observed prolonged survival and response rates exceeding literature data for malignant gliomas.
- Two patients achieved long-lasting complete tumor remissions, a rare outcome in this indication.
Conclusions:
- Targeted TGF-beta2 suppression with AP 12009 represents a promising therapeutic strategy for malignant gliomas.
- AP 12009 may be effective for other aggressive, TGF-beta2-overexpressing tumors.
- Further investigation into AP 12009 for glioma treatment is warranted.
